Drug class in one race
S1P receptor drugs for Multiple Sclerosis
5 tracked S1P receptor drugs in the Multiple Sclerosis race. The class explanation lives on the S1P receptor page; the full indication pipeline across every mechanism is on the Multiple Sclerosis page.
5 approved / phase 4
Head-to-head evidence: Mayzent vs Ponesimod · Mayzent vs Tascenso ODT · fingolimod (Gilenya) vs Mayzent · Mayzent vs ozanimod · Ponesimod vs Tascenso ODT · fingolimod (Gilenya) vs Ponesimod